Industry, FDA Coming Together On Risk Management For Marketed Devices
This article was originally published in The Pink Sheet Daily
Executive Summary
Representatives from the device industry and FDA are trying to establish common ground for how to assess and manage risk of potential safety or compliance issues that crop up for marketed devices.
You may also be interested in...
Abbott Recalls Freestyle InsuLinx Glucose Meter Following Similar J&J Recall
Abbott initiates a global recall of its FreeStyle InsuLinx blood glucose meter, after a similar recall of J&J/LifeScan glucose meter, due to device’s inaccurate reading at high blood glucose levels.
Regulatory News In Brief
Johnson & Johnson/LifeScan is recalling nearly 2 million blood glucose meters in the U.S. and overseas. Court rules in favor of FDA in Cytori 510(k) substantial equivalence case. More regulatory news.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.